- Home
- SMTC vs ACAD Comparison
SMTC vs ACAD Comparison
Compare SMTC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTC
- ACAD
- Stock Information
- Founded
- SMTC 1960
- ACAD 1993
- Country
- SMTC United States
- ACAD United States
- Employees
- SMTC N/A
- ACAD N/A
- Industry
- SMTC Semiconductors
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SMTC Technology
- ACAD Health Care
- Exchange
- SMTC Nasdaq
- ACAD Nasdaq
- Market Cap
- SMTC 3.2B
- ACAD 3.5B
- IPO Year
- SMTC N/A
- ACAD 2004
- Fundamental
- Price
- SMTC $53.07
- ACAD $23.25
- Analyst Decision
- SMTC Strong Buy
- ACAD Buy
- Analyst Count
- SMTC 12
- ACAD 18
- Target Price
- SMTC $60.83
- ACAD $27.94
- AVG Volume (30 Days)
- SMTC 2.1M
- ACAD 1.8M
- Earning Date
- SMTC 08-26-2025
- ACAD 08-06-2025
- Dividend Yield
- SMTC N/A
- ACAD N/A
- EPS Growth
- SMTC N/A
- ACAD N/A
- EPS
- SMTC N/A
- ACAD 1.37
- Revenue
- SMTC $954,242,000.00
- ACAD $996,283,000.00
- Revenue This Year
- SMTC $15.81
- ACAD $13.28
- Revenue Next Year
- SMTC $9.69
- ACAD $11.06
- P/E Ratio
- SMTC N/A
- ACAD $16.99
- Revenue Growth
- SMTC 13.83
- ACAD 22.42
- 52 Week Low
- SMTC $24.05
- ACAD $13.40
- 52 Week High
- SMTC $79.52
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- SMTC 68.76
- ACAD 63.39
- Support Level
- SMTC $50.15
- ACAD $22.09
- Resistance Level
- SMTC $54.44
- ACAD $23.60
- Average True Range (ATR)
- SMTC 2.16
- ACAD 0.70
- MACD
- SMTC 0.23
- ACAD 0.11
- Stochastic Oscillator
- SMTC 88.32
- ACAD 87.32
About SMTC Semtech Corporation
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems and IoT Connected Services. The majority of the company's revenue is earned through Analog Mixed Signal and Wireless segment. Geographically majority of the company's revenue is earned from Asia Pacific region, company also operates in North America and Europe.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.